Prairiewood Capital, LLC Catalyst Pharmaceuticals, Inc. Transaction History

Prairiewood Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 13, 2022	SELL	$7.06 - $15.52 $1.7 Million - $3.74 Million	-241,012 Reduced 93.55%	16,609 $213,000
Q2 2022 Jul 13, 2022	SELL	$6.23 - $8.57 $2,815 - $3,873	-452 Reduced 0.18%	257,621 $1.81 Million
Q1 2022 Apr 20, 2022	SELL	$5.31 - $8.31 $17,682 - $27,672	-3,330 Reduced 1.27%	258,073 $2.14 Million
Q4 2021 Jan 20, 2022	SELL	$5.21 - $7.45 $31,437 - $44,953	-6,034 Reduced 2.26%	261,403 $1.77 Million
Q3 2021 Oct 13, 2021	BUY	$4.85 - $6.04 $52,724 - $65,660	10,871 Added 4.24%	267,437 $1.42 Million
Q2 2021 Jul 13, 2021	BUY	$4.29 - $6.05 $5,577 - $7,865	1,300 Added 0.51%	256,566 $1.48 Million
Q1 2021 Apr 13, 2021	BUY	$3.45 - $4.69 $144,327 - $196,201	41,834 Added 19.6%	255,266 $1.18 Million
Q4 2020 Jan 15, 2021	BUY	$2.97 - $3.83 $633,893 - $817,444	213,432 New	213,432 $713,000

327

94.1M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.33B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Prairiewood Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Prairiewood Capital, LLC with notifications on news.